Your Article Summary
See Latest ArticlesThe effects of an olmesartan medoxomil–based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older
The Journal of Clinical Hypertension, 07/01/09
Kereiakes DJ et al. – An olmesartan medoxomil (OM)-based treatment algorithm effectively lowers blood pressure (BP) in an elderly pt population throughout 24-hr dosing interval without compromising tolerability.
Methods- Study of the effect of OM ± hydrochlorothiazide (HCTZ) on mean 24-hr ambulatory BP, mean seated cuff (Se)BP, and SeBP goal achievement in hypertensive pts age ≥65 yrs
- After 2- to 3-wk placebo run-in, OM 20 mg, uptitrated to 40 mg, then added HCTZ 12.5 mg to 25 mg stepwise at 3-wk intervals if SeBP remained ≥120/70 mm Hg
- Primary endpoint: change from baseline in mean 24-hr ambulatory systolic BP
- At study end, mean 24-hr ambulatory BP decreased by 25.7/12.3 mm Hg (150 pts) and mean SeBP by 25.4/10.5 mm Hg (176 pts)
- Drug-related treatment-emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), in 11.8% of pts
Related Articles
Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke
Hypertension Research, 11/11/09
Relevance Score: 87%
Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension
Hypertension Research, 11/10/09
Relevance Score: 84%
Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
Diabetologia - Clinical and Experimental Diabetes and Metabolism, 11/10/09
Relevance Score: 80%
Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner
Nephrology Dialysis Transplantation, 10/08/09
Relevance Score: 80%
Today in Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Long-Term Stability of Cardiovascular and Catecholamine Responses to Stress Tests. An 18-Year Follow-Up Study
Hypertension, 12/07/09
Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Convertng Enzyme 2. Prevention of Angiotensin II–Dependent Hypertension
Hypertension, 12/07/09
Non-congenital heart disease associated pediatric pulmonary arterial hypertension
Progress in Pediatric Cardiology, 12/07/09